Clinical Trial
doi: 10.1212/01.wnl.0000071218.34009.af.
Longitudinal MRI study: the effects of azathioprine in MS patients refractory to interferon beta-1b
Affiliations
- PMID: 12796549
- DOI: 10.1212/01.wnl.0000071218.34009.af
Item in Clipboard
Clinical Trial
Longitudinal MRI study: the effects of azathioprine in MS patients refractory to interferon beta-1b
Neurology.
.
Abstract
An open-label study was performed to assess the effectiveness of oral azathioprine (AZA) on augmenting the response to interferon beta-1b (IFNbeta-1b) in patients with treatment-refractory relapsing-remitting MS. Six IFNbeta-1b-treated MS patients with continued disease activity were studied on IFNbeta-1b and AZA therapy for a median period of 15 months. A 69% reduction in the number of contrast-enhancing lesions was observed during the combination therapy (p = 0.002).
Similar articles
-
The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.J Neurol. 2008 Sep;255(9):1315-23. doi: 10.1007/s00415-008-0879-6. Epub 2008 Sep 25. J Neurol. 2008. PMID: 18825438 Clinical Trial.
-
A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging.Mult Scler. 2005 Jun;11(3):296-301. doi: 10.1191/1352458505ms1154oa. Mult Scler. 2005. PMID: 15957510 Clinical Trial.
-
Azathioprine and interferon beta-1b treatment in relapsing-remitting multiple sclerosis.J Neurol Neurosurg Psychiatry. 2001 Mar;70(3):413-4. doi: 10.1136/jnnp.70.3.413. J Neurol Neurosurg Psychiatry. 2001. PMID: 11181879 Free PMC article. No abstract available.
-
Spotlight on Interferon-beta-1b in relapsing-remitting and secondary progressive multiple sclerosis.BioDrugs. 2004;18(5):343-7. doi: 10.2165/00063030-200418050-00006. BioDrugs. 2004. PMID: 15377176 Review.
-
History of modern multiple sclerosis therapy.J Neurol. 2005 Sep;252 Suppl 3:iii3-iii9. doi: 10.1007/s00415-005-2010-6. J Neurol. 2005. PMID: 16170498 Review.
Cited by
-
Managing Disease-Modifying Therapies and Breakthrough Activity in Multiple Sclerosis Patients During the COVID-19 Pandemic: Toward an Optimized Approach.Ther Clin Risk Manag. 2020 Jul 22;16:651-662. doi: 10.2147/TCRM.S257714. eCollection 2020. Ther Clin Risk Manag. 2020. PMID: 32801722 Free PMC article. Review.
-
[Oral cladribine for relapsing-remitting multiple sclerosis: another purine analogue or a genuine therapeutic innovation?].Nervenarzt. 2010 Oct;81(10):1231-41. doi: 10.1007/s00115-010-3040-6. Nervenarzt. 2010. PMID: 20567960 Review. German.
-
Azathioprine for people with multiple sclerosis.Cochrane Database Syst Rev. 2024 Dec 9;12(12):CD015005. doi: 10.1002/14651858.CD015005.pub2. Cochrane Database Syst Rev. 2024. PMID: 39651635 Free PMC article.
-
[Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)].Nervenarzt. 2006 Dec;77(12):1506-18. doi: 10.1007/s00115-006-2220-x. Nervenarzt. 2006. PMID: 17136556 German.
-
Novel composite MRI scale correlates highly with disability in multiple sclerosis patients.Mult Scler Relat Disord. 2015 Nov;4(6):526-35. doi: 10.1016/j.msard.2015.08.009. Epub 2015 Aug 28. Mult Scler Relat Disord. 2015. PMID: 26590659 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
